CA1087074A - Uric acid determination - Google Patents
Uric acid determinationInfo
- Publication number
- CA1087074A CA1087074A CA283,668A CA283668A CA1087074A CA 1087074 A CA1087074 A CA 1087074A CA 283668 A CA283668 A CA 283668A CA 1087074 A CA1087074 A CA 1087074A
- Authority
- CA
- Canada
- Prior art keywords
- solution
- uric acid
- ion
- protein
- multivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/62—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving uric acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
- Y10T436/148888—Uric acid
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A B S T R A C T
An aqueous solution useful in connection with a redox type spectrophotometric or colorimetric determination of uric acid in a biologic fluid is disclosed. The solution contains either a multivalent metallic ion reducible to a lower valence state by uric acid, a water soluble chelating compound capable of complexing with a metallic ion after reduction by uric acid to yield, in complexed form, a colored complex, or a combination of said ion and said chelating compound. The solution also contains, as an added constituent, imidazole, an alpha-amino acid, or a combination thereof. This constituent is present in an amount such that, when said solution contains a biologic fluid containing protein and uric acid, a buffer system such that the pH of the solution is 6 to 12, and a multivalent metal ion, the protein in the fluid does not significantly reduce said multivalent ions present in the solution.
An aqueous solution useful in connection with a redox type spectrophotometric or colorimetric determination of uric acid in a biologic fluid is disclosed. The solution contains either a multivalent metallic ion reducible to a lower valence state by uric acid, a water soluble chelating compound capable of complexing with a metallic ion after reduction by uric acid to yield, in complexed form, a colored complex, or a combination of said ion and said chelating compound. The solution also contains, as an added constituent, imidazole, an alpha-amino acid, or a combination thereof. This constituent is present in an amount such that, when said solution contains a biologic fluid containing protein and uric acid, a buffer system such that the pH of the solution is 6 to 12, and a multivalent metal ion, the protein in the fluid does not significantly reduce said multivalent ions present in the solution.
Description
~087~74 The present invention relates to the determination of uric acid in biologic fluids, and, more particularly, to avoiding protein inter~erence in such a determination.
In the human body, uric acid is the final product of the metabolism of purines, especially adenine and guanine, which are constituents of all nucleic acids. In most other mammals, uric acid is further broken down by the enzyme uricase to allatonin which is highly s~luble. However, man does not possess uricase and, as a result, uric acid is not broken down further in the human body and this can lead to the possibility of elevated serum uric acid concentrations, typically termed hyperuricemia. In turn, hyperuricemia can give rise to the clinical syndrome of gout. Testing for uric acid in human sera is, there~ore, a commonly employed clinical diagnostic procedure.
A redox type of spectrophotometric or colorimetric determination ~or uric acid is a common approach. Uric acid is recognized as being a reductant of multivalent metallic ions and, in the redox approach, this function is utilized.
Thus, the serum sample containing the analyte uric acid is added to a reagant solution containing a multivalent metallic ion, the degree o~ reduction of the metallic ions originally pre~ent heing indicative o~ the concentration o~ analyte uric acid in the serum sample. So that the degree of reduction can be quantitatively ascertained spectrophotometrically or colorimetrically, there i9 also present in the reagent solution a binding compound which i5 capable of complexing with the metallic ion, after reduction by uric acid, to yield, in the so complexed form, a colored complex. The color intensity of the complex is correlatable with the ~7~7~
degree of metallic ion reduction and, in turn, the concentration of uric acid can be determined from a calibration graph constructed from known uric acid concentrations.
There are three common redox type systems now in use. One is the phosphotungstic method wherein uric acid acts to reduce tungsten (VI) to yield the characteristic tungsten blue color, the measurement of which is accomplished at 640 to 720 nm. The other two methods are similar in that ~-uric acid acts as the reducing agent for reducing divalent copper (Cu++) to monovalent copper (Cu~) and in the use o~ a chelating compound which contains two aromatic rings, each of which has a heterocyclic nitrogen atom which combine in complexing with a monovalent copper ion to develop a characteristic color. There are two o~ such chelating compounds in common use; one being neocuproine and the other
In the human body, uric acid is the final product of the metabolism of purines, especially adenine and guanine, which are constituents of all nucleic acids. In most other mammals, uric acid is further broken down by the enzyme uricase to allatonin which is highly s~luble. However, man does not possess uricase and, as a result, uric acid is not broken down further in the human body and this can lead to the possibility of elevated serum uric acid concentrations, typically termed hyperuricemia. In turn, hyperuricemia can give rise to the clinical syndrome of gout. Testing for uric acid in human sera is, there~ore, a commonly employed clinical diagnostic procedure.
A redox type of spectrophotometric or colorimetric determination ~or uric acid is a common approach. Uric acid is recognized as being a reductant of multivalent metallic ions and, in the redox approach, this function is utilized.
Thus, the serum sample containing the analyte uric acid is added to a reagant solution containing a multivalent metallic ion, the degree o~ reduction of the metallic ions originally pre~ent heing indicative o~ the concentration o~ analyte uric acid in the serum sample. So that the degree of reduction can be quantitatively ascertained spectrophotometrically or colorimetrically, there i9 also present in the reagent solution a binding compound which i5 capable of complexing with the metallic ion, after reduction by uric acid, to yield, in the so complexed form, a colored complex. The color intensity of the complex is correlatable with the ~7~7~
degree of metallic ion reduction and, in turn, the concentration of uric acid can be determined from a calibration graph constructed from known uric acid concentrations.
There are three common redox type systems now in use. One is the phosphotungstic method wherein uric acid acts to reduce tungsten (VI) to yield the characteristic tungsten blue color, the measurement of which is accomplished at 640 to 720 nm. The other two methods are similar in that ~-uric acid acts as the reducing agent for reducing divalent copper (Cu++) to monovalent copper (Cu~) and in the use o~ a chelating compound which contains two aromatic rings, each of which has a heterocyclic nitrogen atom which combine in complexing with a monovalent copper ion to develop a characteristic color. There are two o~ such chelating compounds in common use; one being neocuproine and the other
2,2'-bicinchoninate. These compounds, which have the ollowing structural representations, are commonly utilized in the form of the hydrochloride, trihydrate and disodium salts, respectively.
C~13 ~I3 COONa COONa Neocuproine Sodium 2,2'-Bicinchoninate ,~ , . .. .. .. .. . .
1~8707~
With neocuproine, a yellow color is developed in the presence of Cu+ which is measured at 455nm. With the bicinchoninate, a lavender color is formed and absorbance measured at 562nm.
A problem which can be encountered with these redox type determinations of uric acid stems from the fact that the reduction reaction involved is not entirely specific for uric acid, there being other constituents in biologic fluids which also tend to reduce the multivalent ions employed. Except for protein, this problem has been largely overcome by using ~`
as the blank, against which the reagent solution containing the serum sample is measured, an identical solution except for the addition thereto of uricase. The uricase in the blank specifically destroys the serum uric acid therein, thus the resulting absorbance is singularly attributable to the interfering substances in the sample which have reduced the multivalent ions. In turn, the di~ference between the reagent solution with no uricase and the blank is representative of the analyte uric acid concentration in the serum.
As to protein, this is a reductant ~or multivalent lons in alkaline pH. And, since the customary redox methods are accompllshed at A p~l within the ~an~e G to 12, protein lnt~rference aan be a serious problem. Protein is, o~
course, present in a much larger concentration in serum than is uric acid and, thereore, its reductive eect on the muLtivalent ion can in essence swamp the efect o uric acid.
Accordingly, even utilizing a blank containing uricase, the sensitivity o the resulting measurement is simply inadequate or reliable determinations of uric acid unless the reductive .. ~ ,.~ . ~ .... .. .... .. . . . . .. .
707g effect of protein is largely eliminated. With respect to the use o~ the phosphotungstic and bicinchoninate methods, protein removal, such as by dialysis, before determination is ordinarily employed. With neocuproine, there are several test procedures commercially available which apparently do not require protein rernoval. The manner in which the problem with respect to protein interference is avoided is not now known.
In accordance with the present invention, there is provided an aqueous solution which is useful in connection with a redox type spectrophotometric or colorimetric determination of uric acid in a biologic fluid which does not necessitate the removal of protein prior to determination.
An important aspect thereo~ resides in the discovery that imidazole or a water soluble alpha-amino acid can be used to prevent or diminish protein reduction oE a multivalent met~1 ion while not interfering with the reducing action of uric acid on the ion. Accordingly, by including one of these constituents in the reagent solution or in one of the solutions used in formulating the reagent solution, the determination o~ uric acid can be accomplished without the ;~
necessity for prior protein removal. The invention i9 considered to be applicable with respect to redo~ systems a~
cliscussed above. ~ccordingly, any o~ the ~olut.ions illustrated h~rein aan, in keeping wi~h conventional practices, contain preservatives and fillers as well as bufEer systems such that the p~l o~ the reagent solution, aEter addltlon of the biologic fluid thereto, is within the range 6 to 12; this pH range being recognized as most e~fective ~or achieving metallic ion reduction and in keeping the various reagents utilized in solution.
_ q, _ ~087074 Thus, in one of its aspects, the present invention provides an aqueous solution useful in connection with a redox type spectrophotometric or colorimetric determination of uric acid in a biolo~ic fluid. The solution contains either a multivalent metallic ion reducible to a lower valence state by uric acid or a water-soluble chelating compound capable of complexing with a metallic ion after reduction by uric acid to yield, in complexed form, a colored complex. If the solution being fashioned is the final reagent solution to which the biologic fluid is to be added, then it contains a combination of both the ion and the chelating compound. In any event, in keeping with this invention, the solution also contains, as an added constituent, imidazole or an alpha-amino acid. This constituent i9 present in an amount such that, when the solution contains a biologic Eluid, an appropriate bufEer system, and a multivalent metal ion, the protein in the fluid does not reduce the multivalent ions also present in the solution.
In accordance with a preferred aspect of the present invention, the solutions illustrated herein contain both the imidazole and alpha-amino acid. By :lncluding both o~ these ingredients, not only is protein lnt~rference ee~ectiv~ly avoided but, adclitionally, the absorbance of the reagent blank (containing uricase) is lowered thereby increasing the sensitivity of the determination and the color ~tAbility Oe the test solution is also enhanced. The solutions of the present invention are considered to be particularly useful in connection with 2,2'-bicinchoninate method for uric acid determination. The combined use of 37~74 imidazole and the amino acid has the further advantage that the solubility of the chelating compound is increased, particularly at the preferred pH range of 6.5-9.5.
The following example illustrates the present invention. All parts and percentages are by weight unless otherwise indicated.
Three solutions containing the following ingredients, each in 2 liters of deionized water, are prepared:
A. B. C.
Buffer Dy~ Copper 0.4 gm Na2H2 ethylene- 56.84 gm Imidazole 1.67 gm Cupric diaminetetraacetic sulfate acid 2H20 pentahydrate 18.0 gm Tris-hydroxy- 6.68 gm Boric acid methylaminomethane 12.2 gm Boric acid8.32 gm Alanine 100 ml Ethylene glycol 100.0 gm Tris-(hydroxy-methyl)-aminomethane 8.0 gm Polyvinylpyrroli-done pH - 8.530.0 gm Succinic acid ; 3 ml Phenoxyethyanol 18.68 gm Disodium 2,2'-bicinchoninate A color reagent is first formulated by mixlng together equal volumes of the dye solution B. ancl the copper solution C. within our hours prior to use. A uricase solution is also prepared by mixing 120 ml. of the buffer A.
with 2 IU lyophilized uricase (Candida Utilis yeast) which is stored prior to use at 4C. in a tightly capped vessel.
The test reagent is prepared by adding 0.1 ml. of serum sample to 1.0 ml. of buffer A. and incubating that solution at 37C. for 15 minutes followed by 5 minutes of incubation at room temperature in a water bath. Then, 3 ml.
~87074 of the color reagent is added thereto, the solution allowed to stand for 15 minutes at room temperature to permit color development and the absorbance then read at 562nm. The blank against which the test solution is read is prepared in an identical fashion except that 0.1 ml. of the serum sample is added to 1.0 ml. of the uricase solution instead of to the buffer A.
Preferably, reagent blanks are prepared for both the test and blank solutions by using water as the sample in each of the above procedures instead of serum. Using such blanks for the purpose of setting absorbance at O will correct for any reductive interference which may be present in the uricase solution. Similarly, in order to construct a calibration graph, calibrator solutions are run in the test procedure in the same manner as serum.
With respect to this procedure, Beer's law ls applicable up to a concentration of at least 20 mg/dl. For uric acid concentrations in excess of this value, isotonic saline (0.85 grams sodium chloride/al) can be used to appropriately dilute the serum sample to bring the concentration within the desired range.
While the pre9ent invention has been illustrated with respect to a preEerred embodiment, tt Ls to be understood that .Lt :Ls not to be limited to only that embodiment. On the contrary, it is intended to cover all alternatives and modifications thereof as can be included within the spirit and scope of the invention as de~ined in the appended claims. For example, while the example has illustrated the invention in connection with the use of a ; 30 copper-- bicinchoninate redox system, the invention is considered applicable with respect to any redox system and, ; in particular, also to the phosphotungstic and neocuproine ~ methods.
.
_ 7 _ ~L087C~74 Fur~hermore, while the example has specifically shown the use of imidazole and alanine originally present in the solution containing the 2,2'-bicinchoninate, it is to be understood that these added constituents, or only one of them, can be originally included in either the buf:Eer solution or the metallic ion solution or all three solutions :
can be preformulated and the imidazole and/or organic acid added thereto. In this respect, the important aspect is that the added constituent be present prior to the time at which the serum containing protein and uric acid is brought into contact with the multivalent ion.
Moreover, it is to be understood that the invention, though illustrated with respect to alanine as the amino acid, can be practiced with any other o~ the recognized water soluble alpha-amino acids. Furthermore, as to the amount o~ imidazole and/or amino acid employed, this mu~t be sufficient to prevent the discussed protein interference and an appropriate concentration thereof can be determined by simple experimentation once the particular redox system has been selected. In general, based on the use of 0.1 ml. of ; serum, about 10 mg to 100 mg o~ added constituent~ is use~ul with about 50 mg being particularly pre~erred.
. -- 8 --........
C~13 ~I3 COONa COONa Neocuproine Sodium 2,2'-Bicinchoninate ,~ , . .. .. .. .. . .
1~8707~
With neocuproine, a yellow color is developed in the presence of Cu+ which is measured at 455nm. With the bicinchoninate, a lavender color is formed and absorbance measured at 562nm.
A problem which can be encountered with these redox type determinations of uric acid stems from the fact that the reduction reaction involved is not entirely specific for uric acid, there being other constituents in biologic fluids which also tend to reduce the multivalent ions employed. Except for protein, this problem has been largely overcome by using ~`
as the blank, against which the reagent solution containing the serum sample is measured, an identical solution except for the addition thereto of uricase. The uricase in the blank specifically destroys the serum uric acid therein, thus the resulting absorbance is singularly attributable to the interfering substances in the sample which have reduced the multivalent ions. In turn, the di~ference between the reagent solution with no uricase and the blank is representative of the analyte uric acid concentration in the serum.
As to protein, this is a reductant ~or multivalent lons in alkaline pH. And, since the customary redox methods are accompllshed at A p~l within the ~an~e G to 12, protein lnt~rference aan be a serious problem. Protein is, o~
course, present in a much larger concentration in serum than is uric acid and, thereore, its reductive eect on the muLtivalent ion can in essence swamp the efect o uric acid.
Accordingly, even utilizing a blank containing uricase, the sensitivity o the resulting measurement is simply inadequate or reliable determinations of uric acid unless the reductive .. ~ ,.~ . ~ .... .. .... .. . . . . .. .
707g effect of protein is largely eliminated. With respect to the use o~ the phosphotungstic and bicinchoninate methods, protein removal, such as by dialysis, before determination is ordinarily employed. With neocuproine, there are several test procedures commercially available which apparently do not require protein rernoval. The manner in which the problem with respect to protein interference is avoided is not now known.
In accordance with the present invention, there is provided an aqueous solution which is useful in connection with a redox type spectrophotometric or colorimetric determination of uric acid in a biologic fluid which does not necessitate the removal of protein prior to determination.
An important aspect thereo~ resides in the discovery that imidazole or a water soluble alpha-amino acid can be used to prevent or diminish protein reduction oE a multivalent met~1 ion while not interfering with the reducing action of uric acid on the ion. Accordingly, by including one of these constituents in the reagent solution or in one of the solutions used in formulating the reagent solution, the determination o~ uric acid can be accomplished without the ;~
necessity for prior protein removal. The invention i9 considered to be applicable with respect to redo~ systems a~
cliscussed above. ~ccordingly, any o~ the ~olut.ions illustrated h~rein aan, in keeping wi~h conventional practices, contain preservatives and fillers as well as bufEer systems such that the p~l o~ the reagent solution, aEter addltlon of the biologic fluid thereto, is within the range 6 to 12; this pH range being recognized as most e~fective ~or achieving metallic ion reduction and in keeping the various reagents utilized in solution.
_ q, _ ~087074 Thus, in one of its aspects, the present invention provides an aqueous solution useful in connection with a redox type spectrophotometric or colorimetric determination of uric acid in a biolo~ic fluid. The solution contains either a multivalent metallic ion reducible to a lower valence state by uric acid or a water-soluble chelating compound capable of complexing with a metallic ion after reduction by uric acid to yield, in complexed form, a colored complex. If the solution being fashioned is the final reagent solution to which the biologic fluid is to be added, then it contains a combination of both the ion and the chelating compound. In any event, in keeping with this invention, the solution also contains, as an added constituent, imidazole or an alpha-amino acid. This constituent i9 present in an amount such that, when the solution contains a biologic Eluid, an appropriate bufEer system, and a multivalent metal ion, the protein in the fluid does not reduce the multivalent ions also present in the solution.
In accordance with a preferred aspect of the present invention, the solutions illustrated herein contain both the imidazole and alpha-amino acid. By :lncluding both o~ these ingredients, not only is protein lnt~rference ee~ectiv~ly avoided but, adclitionally, the absorbance of the reagent blank (containing uricase) is lowered thereby increasing the sensitivity of the determination and the color ~tAbility Oe the test solution is also enhanced. The solutions of the present invention are considered to be particularly useful in connection with 2,2'-bicinchoninate method for uric acid determination. The combined use of 37~74 imidazole and the amino acid has the further advantage that the solubility of the chelating compound is increased, particularly at the preferred pH range of 6.5-9.5.
The following example illustrates the present invention. All parts and percentages are by weight unless otherwise indicated.
Three solutions containing the following ingredients, each in 2 liters of deionized water, are prepared:
A. B. C.
Buffer Dy~ Copper 0.4 gm Na2H2 ethylene- 56.84 gm Imidazole 1.67 gm Cupric diaminetetraacetic sulfate acid 2H20 pentahydrate 18.0 gm Tris-hydroxy- 6.68 gm Boric acid methylaminomethane 12.2 gm Boric acid8.32 gm Alanine 100 ml Ethylene glycol 100.0 gm Tris-(hydroxy-methyl)-aminomethane 8.0 gm Polyvinylpyrroli-done pH - 8.530.0 gm Succinic acid ; 3 ml Phenoxyethyanol 18.68 gm Disodium 2,2'-bicinchoninate A color reagent is first formulated by mixlng together equal volumes of the dye solution B. ancl the copper solution C. within our hours prior to use. A uricase solution is also prepared by mixing 120 ml. of the buffer A.
with 2 IU lyophilized uricase (Candida Utilis yeast) which is stored prior to use at 4C. in a tightly capped vessel.
The test reagent is prepared by adding 0.1 ml. of serum sample to 1.0 ml. of buffer A. and incubating that solution at 37C. for 15 minutes followed by 5 minutes of incubation at room temperature in a water bath. Then, 3 ml.
~87074 of the color reagent is added thereto, the solution allowed to stand for 15 minutes at room temperature to permit color development and the absorbance then read at 562nm. The blank against which the test solution is read is prepared in an identical fashion except that 0.1 ml. of the serum sample is added to 1.0 ml. of the uricase solution instead of to the buffer A.
Preferably, reagent blanks are prepared for both the test and blank solutions by using water as the sample in each of the above procedures instead of serum. Using such blanks for the purpose of setting absorbance at O will correct for any reductive interference which may be present in the uricase solution. Similarly, in order to construct a calibration graph, calibrator solutions are run in the test procedure in the same manner as serum.
With respect to this procedure, Beer's law ls applicable up to a concentration of at least 20 mg/dl. For uric acid concentrations in excess of this value, isotonic saline (0.85 grams sodium chloride/al) can be used to appropriately dilute the serum sample to bring the concentration within the desired range.
While the pre9ent invention has been illustrated with respect to a preEerred embodiment, tt Ls to be understood that .Lt :Ls not to be limited to only that embodiment. On the contrary, it is intended to cover all alternatives and modifications thereof as can be included within the spirit and scope of the invention as de~ined in the appended claims. For example, while the example has illustrated the invention in connection with the use of a ; 30 copper-- bicinchoninate redox system, the invention is considered applicable with respect to any redox system and, ; in particular, also to the phosphotungstic and neocuproine ~ methods.
.
_ 7 _ ~L087C~74 Fur~hermore, while the example has specifically shown the use of imidazole and alanine originally present in the solution containing the 2,2'-bicinchoninate, it is to be understood that these added constituents, or only one of them, can be originally included in either the buf:Eer solution or the metallic ion solution or all three solutions :
can be preformulated and the imidazole and/or organic acid added thereto. In this respect, the important aspect is that the added constituent be present prior to the time at which the serum containing protein and uric acid is brought into contact with the multivalent ion.
Moreover, it is to be understood that the invention, though illustrated with respect to alanine as the amino acid, can be practiced with any other o~ the recognized water soluble alpha-amino acids. Furthermore, as to the amount o~ imidazole and/or amino acid employed, this mu~t be sufficient to prevent the discussed protein interference and an appropriate concentration thereof can be determined by simple experimentation once the particular redox system has been selected. In general, based on the use of 0.1 ml. of ; serum, about 10 mg to 100 mg o~ added constituent~ is use~ul with about 50 mg being particularly pre~erred.
. -- 8 --........
Claims (10)
OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. In an aqueous solution useful in connection with a redox type spectrophotometric or colorimetric determination of uric acid in a biologic fluid comprising a multivalent metallic ion reducible to a lower valence state by uric acid and a water soluble chelating compound capable of complexing with said metallic ion after reduction by uric acid to yield, in complexed form, a colored complex; the improvement wherein said solution also contains, as an added constituent, imidazole, or a combination of imidazole and a water soluble alpha-amino acid, said constituent being present in an amount such that, when said solution contains a biologic fluid con-taining protein and uric acid, a buffer system such that the pH of the solution is 6 to 12, and a multivalent metal ion, said protein in said fluid does not significantly reduce said multivalent ions present in said solution.
2. The solution of claim 1 wherein the multivalent ion is divalent copper reducible by uric acid to monovalent copper and said chelating compound contains two aromatic rings, each of which has a heterocyclic nitrogen atom which combine in complexing with the monovalent copper ion.
3. The solution of claim 2 wherein the chelating compound is neocuproine or a 2,2'-bicinchoninate salt.
4. The solution of claim 3 wherein the chelating compound is disodium 2,2'-bicinchoninate.
5. The solution of claim 4 wherein said added constit-uent is imidazole.
- Page 1 of Claims -
- Page 1 of Claims -
6. The solution of claim 4 wherein said added constit-uent is a combination of imidazole and a water soluble alpha-amino acid.
7. The solution of claim 6 wherein said amino acid is alanine.
8. The solution of claim 7 wherein said buffer system maintains the pH of the solution at about 6.5-9.5 after the addition thereto of said sample of biologic fluid.
9. In an aqueous solution useful in connection with a redox type spectrophotometric or colorimetric determination of uric acid in a biologic fluid comprising a divalent copper ion reducible to a monovalent copper ion by uric acid, disodium 2,2'-bicinchoninate and a buffer system to maintain the pH
of the solution at about 6.5-9.5 after the addition thereto of a sample of biologic fluid containing uric acid and protein; the improvement wherein said solution also contains imidazole and a water soluble alpha-amino acid in an amount such that said protein in said fluid does not significantly reduce said multivalent ions present in said solution.
of the solution at about 6.5-9.5 after the addition thereto of a sample of biologic fluid containing uric acid and protein; the improvement wherein said solution also contains imidazole and a water soluble alpha-amino acid in an amount such that said protein in said fluid does not significantly reduce said multivalent ions present in said solution.
10. The solution of claim 9 wherein said amino acid is alanine.
- Page 2 of Claims -
- Page 2 of Claims -
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/710,801 US4072627A (en) | 1976-08-02 | 1976-08-02 | Uric acid determination |
| US710,801 | 1976-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1087074A true CA1087074A (en) | 1980-10-07 |
Family
ID=24855602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA283,668A Expired CA1087074A (en) | 1976-08-02 | 1977-07-28 | Uric acid determination |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4072627A (en) |
| CA (1) | CA1087074A (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4207203A (en) * | 1970-04-17 | 1980-06-10 | Sherwood Medical Industries Inc. | Uric acid standard solutions |
| DE2744046A1 (en) * | 1977-09-30 | 1979-04-12 | Boehringer Mannheim Gmbh | QUICK DIAGNOSTIC FOR DETERMINING URIC ACID IN BODY LIQUIDS |
| US4224034A (en) * | 1978-09-07 | 1980-09-23 | American Monitor Corporation | Assay of iron and iron binding protein reagents and methods |
| US4885240A (en) * | 1986-09-04 | 1989-12-05 | Eastman Kodak Company | Use of organic buffers to reduce dehydroascorbic acid interference in analytical methods |
| US6699720B1 (en) * | 2000-05-26 | 2004-03-02 | Development Center For Biotechnology | Interference-eliminating membranes, test strips, kits and methods for use in uric acid assay |
| CN112972127B (en) * | 2021-02-01 | 2022-03-18 | 杭州可靠护理用品股份有限公司 | Baby diaper with urine display line |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3282649A (en) * | 1962-05-04 | 1966-11-01 | Donald L Bittner | Determination of oxidizing and reducing substances |
| US3536448A (en) * | 1967-07-28 | 1970-10-27 | Miles Lab | Uric acid detection |
| US3528777A (en) * | 1968-09-27 | 1970-09-15 | Hycel Inc | Process and compositions for determination of uric acid in blood serum |
| US3649198A (en) * | 1970-05-19 | 1972-03-14 | Pfizer & Co C | Diagnostic method for the determination of uric acid in blood |
| GB1282089A (en) * | 1970-10-28 | 1972-07-19 | Miles Lab | Composition for the detection of uric acid |
| US3928137A (en) * | 1971-10-20 | 1975-12-23 | Mallinckrodt Inc | Reagent formulation for uric acid assay |
| US3794467A (en) * | 1971-10-28 | 1974-02-26 | Du Pont | Removing substances from a liquid by precipitation in porous glass beads |
| US3822115A (en) * | 1972-08-30 | 1974-07-02 | Medico Electronic Inc | Method and reagent for uric acid determination |
| DE2307052C2 (en) * | 1973-02-13 | 1974-10-31 | Boehringer Mannheim Gmbh, 6800 Mannheim | Uric acid standard |
-
1976
- 1976-08-02 US US05/710,801 patent/US4072627A/en not_active Expired - Lifetime
-
1977
- 1977-07-28 CA CA283,668A patent/CA1087074A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| US4072627A (en) | 1978-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Carroll et al. | A simplified alkaline phosphotungstate assay for uric acid in serum | |
| Kaplan | The determination of urea, ammonia, and urease | |
| Fawcett et al. | A rapid and precise method for the determination of urea | |
| US4308027A (en) | Method and composition for direct determination of iron in blood serum | |
| JPH11504808A (en) | Measurement of glycated protein | |
| EP0215170B1 (en) | Single color reading method for determining fructosamine | |
| US3934977A (en) | Reagent and method for determining total calcium in body fluids | |
| CA1087074A (en) | Uric acid determination | |
| EP0490286B1 (en) | Enzymatic composition for ethanol assay | |
| EP0137400B1 (en) | Determination of unsaturated iron-binding capacity | |
| EP0510190B1 (en) | Reagent and method for serum iron assay | |
| Carter | Spectrophotometric submicrogram serum zinc assay: an application for the routine service laboratory | |
| US3822115A (en) | Method and reagent for uric acid determination | |
| EP0433977B1 (en) | Method for optical measurement of bilirubin and reagent therefor | |
| US4030885A (en) | Bilirubin determination | |
| US5888828A (en) | Kit for measuring urea nitrogen | |
| US4563429A (en) | Bilirubin assay | |
| EP0091913B1 (en) | Uric acid assay and reagent system therefor | |
| US5055398A (en) | Process for measuring the concentration of a component in body fluid such as urine or blood | |
| YUKI et al. | A new method for the determination of serum uric acid by measuring allantoin produced by the action of uricase | |
| JPH05111396A (en) | Method for measuring activity of creatine kinase and reagent used therefor | |
| CA1055825A (en) | Calibrator albumin composition | |
| CN106706623A (en) | Kit for rapidly detecting ischemia modified albumin and application of kit | |
| CA1119923A (en) | Uric acid standard solutions | |
| JP2761768B2 (en) | Method for determining NADH and method for determining bile acid using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |